- Animal health company Zoetis Inc (NYSE: ZTS) received the European Commission's marketing approval for Solensia (frunevetmab), an injectable monoclonal antibody for the alleviation of pain associated with osteoarthritis in cats.
- Solensia targets Nerve Growth Factor (NGF), a key player in osteoarthritis pain. The veterinarian delivers the treatment as a monthly injection (under the skin).
- In November last year, the Commission approved a similar product, Librela (bedinvetmab), for dogs.
- Price Action: ZTS stock closed 4.7% lower at $160 on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
